Secondary prevention after myocardial infarction: a review of short-term acute phase trials.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D001145:Arrhythmias, Cardiac / Q000188:drug therapy; D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects; D002986:Clinical Trials as Topic; D004206:Disopyramide / Q000627:therapeutic use; D004311:Double-Blind Method; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D005947:Glucose / Q000627:therapeutic use; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D008012:Lidocaine / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control*; D011188:Potassium / Q000627:therapeutic use; D011342:Procainamide / Q000627:therapeutic use; D011802:Quinidine / Q000627:therapeutic use; D011897:Random Allocation
D000319:Adrenergic beta-Antagonists; D000889:Anti-Arrhythmia Agents; D000925:Anticoagulants; D005343:Fibrinolytic Agents; D007328:Insulin; C030396:glucose-insulin-potassium cardioplegic solution; D008012:Lidocaine; D006821:Hyaluronoglucosaminidase; D004206:Disopyramide; D011802:Quinidine; D005947:Glucose; D011342:Procainamide; D001241:Aspirin; D011188:Potassium